Late breaker abstracts for the World Hepatitis Summit are now closed!

Submissions for late breaker abstracts were for individuals, groups and organisations.  

Abstracts must have provided an overview of an individual or an organisation’s work and its contribution to local or national responses to viral hepatitis. 

Authors of successful submissions will be invited to present their work at the World Hepatitis Summit 2024 in Lisbon, Portugal. 

Important Dates – The submission process for late breaker abstracts for the WHS 2024 is now closed.

Abstracts - World Hepatitis Summit

Abstract categories

Abstracts on hepatitis A, B, C, D and E are welcome in all categories.  

We particularly encourage submissions from civil society organisations and people with lived experience.  

Please submit your abstract under one of the following categories: 

  1. Innovations – in technologies and/or service delivery including decentralisation, task-shifting, simplification and community-led initiatives.
  2. Integration – Liver cancer, HIV, non-communicable diseases, tuberculosis , maternal and child health, primary care or other relevant areas. 
  3. Advocacy, awareness and education campaigns. 
  4. Combatting stigma and discrimination. 
  5. The power and impact of lived experience. 
  6. Prevention of mother-to-child transmission of viral hepatitis and hepatitis in children. 
  7. The role of good data, surveillance, monitoring and evaluation in elimination. 
  8. Partnerships (Private / Public, Cross-sectorial). 
  9. Financing for viral hepatitis (including investment cases and financing models). 
  10. Universal Health Coverage and person-centred approaches. 

Submission guidelines

Selection process

Notifications of acceptance or rejection will be sent to submitting authors on: 

First round:        w/c 11 December 2023

Late breaker:     w/c 24 January 2024

Authors whose submissions have been accepted will receive further instructions for the presentation of their submissions.

If you have any queries, please contact WHS@serenevents.com

Hepatitis and PWID/harm reduction 


11:35 – 11:40  

Chair: WHO – Intro and set the scene.  


11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 


11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 


12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.


12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 


12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 


12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  


12:25 – 12:30 

Q&A and closing remarks   

The role of decentralised and community-led services in accelerating progress towards elimination.

Role of harm reduction.